University of Cincinnati, Gardner Neuroscience Institute

Cincinnati, Ohio 45267-0525

3 studies enrolling now · 10 studies all time

What they study most

Becker Muscular Dystrophy, DM1, Dystrophy Myotonic, Focal Segmental Glomerulosclerosis (FSGS), Focal Seizures, Frontotemporal Dementia, Generalized Myasthenia Gravis, Myotonia, Myotonic Disorders, Myotonic Dystrophy, Myotonic Dystrophy 1, Myotonic Dystrophy Type 1

Studies at this site

• A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures — Recruiting now
• Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy — Enrolling by invitation
• Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) — Running, not enrolling
• Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 — Enrolling by invitation
• A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis — Running, not enrolling
• A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD) — Completed
• Global Study of Del-desiran for the Treatment of DM1 — Running, not enrolling
• Continuation Study for Latozinemab — Stopped early
• A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3) — Stopped early
• A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS) — Stopped early